methyl (2Z)-2-[5-(ethoxycarbonylamino)-1,2,4-thiadiazol-3-yl]-2-trityloxyiminoacetate | 331780-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: methyl (2Z)-2-[5-(ethoxycarbonylamino)-1,2,4-thiadiazol-3-yl]-2-trityloxyiminoacetate
• CAS: 331780-39-3
• 化学式: C₂₇H₂₄N₄O₅S
• 分子量: 516.6
• InChiKey: SHIXYLPEFYFKLM-SWKFRHMKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  140
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl (2Z)-2-[5-(ethoxycarbonylamino)-1,2,4-thiadiazol-3-yl]-2-trityloxyiminoacetate 、 Sodium hydroxide ethanol 、 盐酸 在 氮气 、 水 、 甲苯 作用下， 反应 15.0h， 以gave 15.44 grams of the title compound as a white fluffy solid的产率得到(Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(triphenylmethoxyimino)acetic acid
  参考文献：
  名称：

  7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof

  摘要：

  本发明涉及具有公式III或公式IV的头孢菌素前药：或其药学上可接受的盐，其中R′1选自氢和—C（O）CH（NH2）CH3的群组，R′2选自由哺乳动物中的酶水解的酰基基团和氢的群组，但当R′1或R′2为氢时，另一个不是氢。A，B，L，G，E和J各自独立地为氮或碳，以使各自的环从所述提供的群组中选择，前提是当仅将—CH2—S—CH2CH2NHR′2基团附加到所述杂环基团的碳原子时，Q选自氮和—CX的群组，其中X选自氢和氯的群组。

  公开号：

  US06723716B1

文献信息

• 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF
  申请人：Essential Therapeutics, Inc.

  公开号：EP1222194A1

  公开（公告）日：2002-07-17
• US6723716B1
  申请人：——

  公开号：US6723716B1

  公开（公告）日：2004-04-20
• [EN] 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF<br/>[FR] ANTIBIOTIQUES A L'ACIDE 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIQUE ET PROMEDICAMENTS DE CES DERNIERS
  申请人：MICROCIDE PHARMACEUTICALS INC

  公开号：WO2001021623A1

  公开（公告）日：2001-03-29

  The present invention includes novel (7R)-7-acylamino-3-heteroarylthio-3-cephem-4-carboxylic acids or their pharmacologically acceptable salts and prodrugs thereof, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to β-lactam antibiotics and are useful as antibacterial agents. The invention also relates to novel intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.
• 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
  申请人：Essential Therapeutics, Inc.

  公开号：US06723716B1

  公开（公告）日：2004-04-20

  The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.

  本发明涉及具有公式III或公式IV的头孢菌素前药：或其药学上可接受的盐，其中R′1选自氢和—C（O）CH（NH2）CH3的群组，R′2选自由哺乳动物中的酶水解的酰基基团和氢的群组，但当R′1或R′2为氢时，另一个不是氢。A，B，L，G，E和J各自独立地为氮或碳，以使各自的环从所述提供的群组中选择，前提是当仅将—CH2—S—CH2CH2NHR′2基团附加到所述杂环基团的碳原子时，Q选自氮和—CX的群组，其中X选自氢和氯的群组。